News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Treatment simplification strategies news

Show

From To
Pharmaceutical industry
Glaxo Bets It Can Shake Up HIV Treatment

GlaxoSmithKline PLC is pinning the future of its HIV business on an audacious bet. They hope their latest HIV pill is powerful enough to suppress the virus with the help of just one other drug.

Published
30 August 2016
From
Wall Street Journal
New and experimental HIV treatments
ViiV Healthcare launches phase III programme evaluating a two-drug regimen combining dolutegravir and lamivudine for HIV-1 treatment

The phase III programme comprises two identical studies (GEMINI 1 and 2) comparing a two-drug regimen of dolutegravir plus lamivudine with a three-drug regimen of dolutegravir plus the fixed-dose tablet tenofovir/emtricitabine (Truvada®), as treatment for HIV-1 infection in adults who have not received prior antiretroviral therapy.

Published
16 August 2016
From
ViiV press release
New and experimental HIV treatments
Dolutegravir plus lamivudine dual therapy works well as initial HIV treatment

A two-drug regimen of dolutegravir and the well-tolerated NRTI lamivudine led to sustained viral suppression for most people starting antiretroviral therapy (ART) for the first time in a

Published
25 July 2016
By
Liz Highleyman
New and experimental HIV treatments
The HIV Treatment Pipeline

“Depending on when you test positive for HIV, you could be looking at up to eight decades of treatment,” says Tim Horn of Treatment Action Group. “We need drugs that are gentler, kinder, better and cheaper.”

Published
28 June 2016
From
Poz
Treatment simplification strategies
Two-drug ART with dolutegravir-lamivudine would be cost-effective and achieve substantial cash savings

Virologically suppressive first-line antiretroviral treatment with a two-drug regimen of dolutegravir (Tivicay) and lamivudine would be highly cost effective and could save US health systems

Published
17 December 2015
By
Michael Carter
New and experimental HIV treatments
Two-drug maintenance therapy keeps viral load suppressed and may even have advantages over traditional ART

Two-drug antiretroviral therapy (ART) consisting of ritonavir-boosted atazanavir and lamivudine has comparable or better virological efficacy than traditional three-drug therapy based on ritonavir/atazanavir, according to a poster presentation at

Published
30 November 2015
By
Michael Carter
Treatment simplification strategies
Can dolutegravir dual therapy or monotherapy produce and maintain HIV suppression?

The potent integrase inhibitor dolutegravir taken with a single well-tolerated NRTI was able to fully suppress viral load in people initiating antiretroviral treatment for the first time, while

Published
23 October 2015
By
Liz Highleyman
Pharmaceutical industry
GSK takes on Gilead with new two-drug HIV treatments

GlaxoSmithKline is banking on new long-acting HIV medicines and simple two-drug regimens to close the gap on arch-rival Gilead Sciences.

Published
22 September 2015
From
Reuters
Treatment simplification strategies
Week-on, weekend-off treatment controls viral load in young people

Taking an efavirenz-based antiretroviral regimen during the week and taking no medication on two days over the weekend was just as effective as daily treatment in controlling

Published
25 February 2015
By
Keith Alcorn
New and experimental HIV treatments
Novel two-drug maintenance combination works at least as well as triple therapy: stage set for long-lasting injectable formulation

An oral combination therapy of two antiretroviral drugs, the non-nucleoside rilpivirine (Edurant, also in Eviplera/Complera) and the new integrase inhibitor GSK1265744 (744), was at least as effective as

Published
08 March 2014
By
Gus Cairns
← Prev1...34567Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.